Abstract: The present invention provides methods and compositions for treating arteriosclerotic vascular diseases by cyclohexenone compounds. In some embodiments, the compound in the methods inhibits PDGF-stimulated smooth muscle cell proliferation or migration. In some embodiments, the atherosclerosis is associated with coronary artery disease, aneurysm, arteriosclerosis, myocardial infarction, embolism, stroke, thrombosis, angina, vascular plaque inflammation, vascular plaque rupture, Kawasaki disease, calcification or inflammation. In some embodiments, the compound lowers low-density lipoprotein (LDL) cholesterol in the subject. In some embodiments, the compound maintains a normal low-density lipoprotein (LDL) cholesterol level in the subject.

Abstract: The invention relates to terpene-derived compounds, such as acids, esters thereof, produced by ozonolysis of terpenes, and to alcohols, amides, nitriles derived therefrom, as well as to processes for synthesizing them. Specifically, 2,3,7-trimethyloct-6-en-2-ol, 2,3,7-trimethyloct-7-en-2-ol, or a mixture thereof, produced by Grignard reaction of a terpene derived carboxylate with methyl magnesium bromide is disclosed.

Abstract: The present invention provides methods and compositions for treating neurodegenerative diseases by cyclohexenone compounds.

Abstract: The present invention relates to compounds for counteracting thiol- and amine-based malodors in consumer, industrial and textile products. Also disclosed are a consumer, industrial or textile product containing one of these compounds and a method for counteracting a thiol- or amine-based malodor using these compounds.

Abstract: Provided is a production method of a lipophilic bioactive substance, which includes mixing an aqueous suspension of a microbial cell containing the lipophilic bioactive substance or a microbial cell homogenate thereof and an organic solvent in the presence of a particular surfactant, and extracting the lipophilic bioactive substance into the organic solvent phase. This production method enables extraction without using special dehydrating, drying facility, and without causing a decrease in the yield due to degraded separability between solvent and fungus body component, as well as efficient industrial production.

Abstract: A method for preparing a hop acid mixture having an enantiomeric excess of a (+)-tetrahydro-?-acid is disclosed. In the method, a racemate of a tetrahydro-?-acid is contacted with an amine to form a precipitate having an enantiomeric excess of the (+)-tetrahydro-?-acid. A method for preparing a hop acid is also disclosed. In the method, a racemate of a tetrahydro-?-acid is contacted with an amine to form a precipitate comprising a (+)-tetrahydro-?-acid, and the (+)-tetrahydro-?-acid is isomerized to a hop acid selected from the group consisting of (+)-trans-tetrahydro-iso-?-acids, (?)-cis-tetrahydro-iso-?-acids, and mixtures thereof, and reduced to (+)-trans-hexahydroiso-?-acids and (?)-cis-hexahydroiso-?-acids. An additive for flavoring a malt beverage is also disclosed. The additive includes a bittering agent selected from the group consisting of (+)-trans-tetrahydro-iso-?-acids, (?)-cis-tetrahydro-iso-?-acids, (+)-trans-hexahydroiso-?-acids, (?)-cis-hexahydroiso-?-acids, and mixtures thereof.

Abstract: This invention is directed to an ameliorating agent for a disease based on vesicourethral dyssynergia, comprising, as an active ingredient, 3-(15-hydroxypentadecyl)-2,4,4-trimethyl-2-cyclohexene-1-one, a salt thereof, or a solvate thereof. The disease based on vesicourethral dyssynergia is any of dysuria accompanying a lifestyle-related disease (such as diabetic dysuria), idiopathic dysuria, dysuria after pelvic surgery, dysuria accompanying spinal cord injury, dysuria accompanying spinal canal stenosis, dysuria accompanying benign prostatic hypertrophy, dysuria accompanying high-pressure voiding/high-pressure urine storage, neurogenic or nonneurogenic lower urinary tract symptoms (LUTS), detrusor sphincter dyssynergia, and detrusor bladder neck dyssynergia.

Abstract: Disclosed are compounds that inhibit RNase H activity of retroviruses, for example, a compound of formula (I) wherein R1, R2, and R3 are as described herein, as well as pharmaceutically acceptable salts, solvates, stereoisomers, and prodrugs thereof. Pharmaceutical compositions comprising such compounds, as well as methods of use, and treatment or prevention of infection by human immunodeficiency virus (HIV).

Abstract: Killing of bed bugs is accomplished by bringing the bed bugs into contact with a toxic amount of at least one of the compounds of the structure (I) wherein X is —OH, ?0, or —O(O)CR, wherein R is selected from H and a branched or straight chain, saturated or unsaturated hydrocarbyl group with zero to three double bonds and from 1 to 11 carbon atoms; R1 is H or CH3; R2 is H or CH3; R3 is H or a branched or straight chain, saturated or unsaturated hydrocarbyl group with zero to three double bonds and from 1 to 11 carbon atoms; and wherein the compounds of structure (I) contain from 6 to 20 total carbon atoms in the compounds.

Abstract: A catalyst, its method of preparation and its use for producing aliphatic ketones by subjecting alkanes C3 to C9 to a gas phase catalytic oxidation in the presence of air or oxygen, and, optionally, steam and/or one or more diluting gases. The catalyst comprises a catalytically active mixed metal oxide phase and a suitable support material onto and/or into which the active catalytic phase id dispersed.

Abstract: The present invention relates to methods of treating methylmalonic aciduria and other organic acidurias with tocotrienol quinones, including alpha-tocotrienol quinone, in order to alleviate symptoms of the disease.

Abstract: Provided herein are processes of preparing cyclohexenone compounds useful for cancer treatments and/or diseases.

Abstract: The present application relates to perfume raw materials, perfume delivery systems and consumer products comprising such perfume raw materials and/or such perfume delivery systems, as well as processes for making and using such perfume raw materials, perfume delivery systems and consumer products. Such perfume raw materials and compositions, including the delivery systems, disclosed herein expand the perfume communities' options as such perfume raw materials can provide variations on character and such compositions can provide desired odor profiles.

Abstract: The present invention concerns a compound of formula (I), in the form of any one of its stereoisomers or a mixture thereof, and wherein the dotted line represents a carbon-carbon single or double bond; as well as its use as perfuming ingredient.

Abstract: The present invention relates to 1-(5-ethyl-5-methyl-1-cyclohexen-1-yl)-4-penten-1-one and its use as perfuming ingredient.

Abstract: The present invention refers to thymoquinone, a main constituent of the volatile oil of Nigella sativa, and its protective effect against sepsis syndrome morbidity, mortality and associated organ dysfunctions. In particular, the present invention refers to thymoquinone for use in the prevention and/or treatment of sepsis syndrome. The present invention further refers to a pharmaceutical composition and a kit.

Abstract: The present invention relates to methods of treating Leigh Syndrome and Leigh-like Syndrome with tocotrienol quinones, including alpha-tocotrienol quinone, in order to alleviate symptoms of the disease.

Abstract: Disclosed is a compound isolated from Antrodia camphorata, represented by formula I: wherein R1 is a hydrogen atom or an acetyl group; and a method of inhibiting cancer cell growth by using the compound, the cancer is selected from the group consisting of lung cancer, colon cancer, prostate cancer, liver cancer and breast cancer.

Abstract: The invention provides a method for synthesizing 7-Acetyleno quinone methide compounds that is safe and inexpensive. The method avoids the need for extremely cold reaction temperatures and unlike the prior art does not require any highly explosive materials. The method comprises the steps of: a) performing a condensation reaction between 3,5-di-tert-butyl-4-hydroxybenzaldehyde and a secondary amine thereby forming a secondary amine quinone methide intermediate; b) removing water from the secondary amine quinone methide intermediate by azeotropic distillation; c) adding the dehydrated secondary amine quinone methide intermediate to an organic medium containing a metal acetylide to form a Mannich base intermediate; and d) adding a release agent to the Mannich base intermediate to yield a 7-Acetyleno quinone methide.

Abstract: The present invention provides edible compositions comprising a compound of the present invention, food products comprising such edible compositions and methods of preparing such food products. The present invention also provides methods of reducing the amount of NaCl in a food product, methods of reducing the sodium intake in a diet, and methods of reducing bitter taste in a food product.

Abstract: The invention relates to the use of ?-isophorone as solvent.

Abstract: Disclosed is a compound isolated from Antrodia camphorata, represented by formula I: wherein R1 is a hydrogen atom or an acetyl group; and a method of inhibiting cancer cell growth by using the compound, the cancer is selected from the group consisting of lung cancer, colon cancer, prostate cancer, liver cancer and breast cancer.

Abstract: A method for repelling blood-sucking and biting insects, ticks and mites involving treating an object or area with a blood-sucking and biting insects, ticks and mites repelling effective amount of camphor lactams, verbenone lactams, dolicholactams, dolicholactone, and their precursors, and mixtures thereof, and optionally a carrier.

Abstract: Disclosed are compounds that inhibit RNase H activity of retroviruses, for example, a compound of formula (I) wherein R1, R2, and R3 are as described herein, as well as pharmaceutically acceptable salts, solvates, stereoisomers, and prodrugs thereof. Pharmaceutical compositions comprising such compounds, as well as methods of use, and treatment or prevention of infection by human immunodeficiency virus (HIV).

Abstract: The present invention provides methods of treating humans and animals with terpenes and terpenoids in order to rejuvenate the skin and increase the protective layer against irradiation by ultraviolet radiation (UVR). More specifically it provides terpenes and terpenoids as ingredients that work as persistent UVR blockers. Terpenes and terpenoid compounds support the growth of skin, skin tissue and keratinocytes and additional UVR-blocking by reason of increased stratum corneum thickness and loricrin content. Both terpenes and terpenoids may be applied topically or orally at oral or topical concentrations from about 6 mg to about 600 mg per kilogram of body weight per day effective to stimulate growth of the skin layer and prevent damage from ultraviolet radiation (UVR).

Abstract: With respect to reduced coenzyme Q10, there has been no report about the presence of crystal polymorphism, and it has been considered that a conventionally obtained crystal form is only one form. The present invention relates to a reduced coenzyme Q10 crystal having an endothermic peak indicating melting at 54±2° C. during temperature rise at a rate of 5° C./min by differential scanning calorimetry (DSC), and/or to a reduced coenzyme Q10 crystal showing characteristic peaks at diffraction angles (2?±0.2°) of 11.5°, 18.2°, 19.3°, 22.3°, 23.0° and 33.3° by powder X-ray (Cu—K?) diffraction. The crystal form is a novel reduced coenzyme Q10 crystal which has a higher melting point and a lower solubility in a solvent, and is more excellent in stability than the conventionally known reduced coenzyme Q10 crystal.

Abstract: The invention relates to substituted 5-(cyclohex-2-en-1-yl)penta-2,4-dienes and 5-(cyclohex-2-en-1-yl)pent-2-en-4-ines of the formula (I) and their salts where the radicals R1, R2, R3, R4, [X—Y] and Q are each as defined in the description, to processes for preparation thereof and to the use thereof for enhancing stress tolerance in plants with respect to abiotic stress, and/or for increasing plant yield.

Abstract: The invention relates to substituted vinyl- and alkynylcyclohexenols of the general formula (I) and salts thereof where the R1, R2, R3, R4, R5, [X—Y] and Q radicals are each as defined in the description, to processes for preparation thereof and to the use thereof for enhancing stress tolerance in plants with respect to abiotic stress, and/or for increasing plant yield.

Abstract: The present invention provides novel spiroenones extracted from an alcohol extract of dehulled adlay seeds. The present invention also provides a process for the preparation of the spiroenones and a method for treating breast cancer in a subject, which method comprises administering to said subject an effective amount of the spiroenone and a pharmaceutically acceptable carrier or excipient.

Abstract: A compound of Formula (I) or of a mixture comprising two, three, four, five, six or a plurality of different compounds of Formula (I) for the superadditive enhancement of an olfactory impression. The invention also relates to novel fragrance and/or flavor material compositions which, in addition to a compound of Formula (I) or a mixture thereof, further contains one, two, three or a plurality of further fragrance and/or flavor materials, the fragrance and/or flavor material or the further fragrance and/or flavor materials not being compound of Formula (I).

Abstract: The present invention concerns a compound of formula (I), in the form of any one of its stereoisomers or a mixture thereof, and wherein the dotted line represents a carbon-carbon single or double bond; as well as its use as perfuming ingredient.

Abstract: The invention relates to the use of ?-isophorone as solvent

Abstract: The present invention relates to 1-(5-ethyl-5-methyl-1-cyclohexen-1-yl)-4-penten-1-one and its use as perfuming ingredient.

Abstract: 1-(3/4-isobutyl-1/6-methylcyclohex-3-enyl)methanols and derivatives thereof having appreciable floral and hesperidic odor notes, their use as fragrance ingredient and perfumed products comprising them.

Abstract: Methods for derivatizing the surface of a substrate having a plurality of thiol groups thereon are disclosed herein. The method can include reacting the thiol groups with an o-quinone methide, which can optionally be generated by irradiating an o-quinone methide precursor compound. In some embodiments, the method can advantageously be reversible. Exemplary o-quinone methides having a cyclic alkyne attached thereto, and precursor compounds for generating such compounds, are also disclosed herein.

Abstract: The present invention relates to the use of one or more compounds of the formulae and/or pharmaceutically acceptable salts thereof for inhibiting the oxidation of fatty acids and/or triacylglycerols; and/or the rancidification of products that includes one or more of fatty acids and/or one or a plurality of triacylglycerols; and/or chemical and/or sensory changes of products that includes one or more of fatty acids and/or one or a plurality of triacylglycerols, caused by the action of the oxygen of the air. Corresponding mixtures and orally consumable preparations and methods are also described.

Abstract: Provided is a production method of a lipophilic bioactive substance, which includes mixing an aqueous suspension of a microbial cell containing the lipophilic bioactive substance or a microbial cell homogenate thereof and an organic solvent in the presence of a particular surfactant, and extracting the lipophilic bioactive substance into the organic solvent phase. This production method enables extraction without using special dehydrating, drying facility, and without causing a decrease in the yield due to degraded separability between solvent and fungus body component, as well as efficient industrial production.

Abstract: Methods for using ailylic oxidation catalysts to perform oxidation reactions. In an exemplary method for catalyzing an ailylic oxidation reaction of the present disclosure, the method comprises the step of catalyzing an oxidation of an ailylic compound using an ailylic oxidation catalyst. In at least one embodiment, the ailylic oxidation catalyst comprises palladium, gold, and titanium, In an exemplary embodiment, the ailylic oxidation catalyst comprises 2.5% A?÷2.5% Pd/TiO2.

Abstract: Disclosed are a production method for a ubiquinone powder for use in preparations, including Step 1 of compression molding a ubiquinone crystal powder at a linear molding pressure of from 0.6 to 2.5 tons/cm to obtain a compressed fragment; and Step 2 of grinding the compressed fragment obtained in Step 1 to obtain a powder; and a ubiquinone powder for use in preparations, which is obtained by the subject production method. According to the subject production method, it becomes possible to provide a ubiquinone powder for use in preparations for medicines and health foods, which has a high bulk density, a small angle of repose and excellent handling properties and fluidity, without using an additive such as an excipient, a binder and the like.

Abstract: The present invention relates to methods of treating Ataxia-Telangiectasia (A-T) or Ataxia-telangiectasia like disorder (ATLD) with compounds such as tocotrienol quinones and tocotrienol hydroquinones, including alpha-tocotrienol quinone, in order to alleviate symptoms of the disease.

Abstract: The present invention provides edible compositions comprising a compound of the present invention, food products comprising such edible compositions and methods of preparing such food products. The present invention also provides methods of reducing the amount of NaCl in a food product, methods of reducing the sodium intake in a diet, and methods of reducing bitter taste in a food product.

Abstract: Methods of treating or suppressing pervasive developmental disorders (PDDs) including; autistic disorder, Asperger's syndrome, childhood disintegrative disorder (CDD), Rett's disorder, and PDD-not otherwise specified (PDD-NOS) or attention deficit/hyperactivity disorder (ADHD) comprising administering to a subject in need thereof a therapeutically effective amount of one or more compounds as disclosed herein.

Abstract: To provide a salty taste enhancer which exerts a flavor enhancing effect comparable to sodium chloride without imparting any undesirable flavor such as harsh taste or odd smell, a method for producing the same, a kelp extract comprising the salty taste enhancer, and a food or drink having enhanced salty taste and flavor which comprises the salty taste enhancer or the kelp extract. A salty taste enhancer which comprises a volatile component with a molecular weight of less than 200 derived from a kelp.

Abstract: The present invention relates to a process for the production of formyl cyclohexene derivatives which are suitable as odorants as such or as intermediates for the preparation of further odorants.

Abstract: The present application relates to perfume raw materials, perfume delivery systems and consumer products comprising such perfume raw materials and/or such perfume delivery systems, as well as processes for making and using such perfume raw materials, perfume delivery systems and consumer products. Such perfume raw materials and compositions, including the delivery systems, disclosed herein expand the perfume communities' options as such perfume raw materials can provide variations on character and such compositions can provide desired odor profiles.

Abstract: One or more embodiments of the present invention describe a novel use of capsanthin and/or fatty-acyl ester of capsanthin to inhibit both the differentiation of pre-adipocytes to adipocytes and the accumulation of fat in the adipocytes. One or more embodiments of the present invention are based on findings that capsanthin contained in some natural products such as red pepper, paprika, bell pepper, etc. have anti-adipogenic activity by inhibiting both the differentiation of pre-adipocyte into adipocyte and the accumulation of fat in adipocytes, Therefore, this findings provide a functional food and a pharmaceutical composition wherein capsanthins and the extract of any natural products containing the same components are included in the functional food and the pharmaceutical composition, to offer obesity prevention and/or treatment effects.

Abstract: The present invention provides methods and compositions for treating lung cancer by cyclohexenone compounds.

Abstract: The invention provides a hydrogen storage material comprising a porous carbon material having oxygen-containing functional groups on the surface, and Li bonded to the surface of the porous carbon material. The hydrogen storage material of the invention has more excellent hydrogen storage capacity than the prior art.

Abstract: An object of the present invention is to provide a substance characterized by ability to reduce oxidized coenzyme Q10 and ability to stabilize reduced coenzyme Q10, which contains nutrients, has a favorable taste, and is excellent in general versatility, and a method for using the same. The present invention relates to a method for producing reduced coenzyme Q10 comprising reducing oxidized coenzyme Q10 with a particular amino acid. The present invention also relates to a method for stabilizing reduced coenzyme Q10 in the presence of a particular amino acid and a composition stabilized by the method.

Abstract: The present invention relates to a novel application of a compound. The compound 4--2,3-dimethoxy-6-methyl-5-(3,7,11-trimethyl-dodeca-2,6,10-trienyl)-cyclohex-2-enone of the invention is isolated and purified from the extracts of Antrodia camphorata, which can be applied for inhibiting the survival of pancreatic cancer cells and be used as a pharmaceutical composition to inhibit the pancreatic tumor growth.